Intermediate Capital Group has completed the acquisition of SuanFarma from ProA Capital, a private equity firm based in Spain.

Based in the UK, Intermediate Capital Group is an asset management firm, while SuanFarma, is a Spanish supplier of pharmaceuticals to the veterinary and nutraceutical industry.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The transaction will enable the target company to expand its production capacity and develop its pharmaceutical business globally.

Banco Santander and Garrigues were appointed as financial and legal advisers to ProA Capital for the acquisition.

Novartis has sold its 36.5% interest in a consumer healthcare joint venture to GlaxoSmithKline (GSK) for $13bn.

“Novartis has sold its 36.5% interest in a consumer healthcare joint venture to GlaxoSmithKline (GSK) for $13bn.”

The transaction will be closed in the second quarter of this year subject to GSK shareholder approval and other necessary regulatory approvals.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

GSK will become the sole owner of the joint venture, upon completion of the transaction.

Based in Switzerland, Novartis is a pharmaceutical company that manufactures generic drugs, over-the-counter drugs and vaccines, while GlaxoSmithKline (GSK) is a research-based pharmaceutical and healthcare company based in the UK.

The transaction will enable Novartis to focus on its core businesses.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact